Medical Condition News

RSS

AI analysis of Reddit reveals public interest in GLP-1 drugs for weight loss and mental health benefits

Researchers analyzed over 391,000 Reddit discussions using AI to study public perceptions of GLP-1 RAs, finding high interest in weight loss, side effects, and access issues, with mostly neutral-to-positive sentiment.

14 Jul 2024

New brain targets for GLP1-based obesity drugs may reduce weight without nausea

Researchers identified distinct hindbrain GLP1R neurons driving satiety and aversion, offering new targets for effective, side-effect-free obesity treatments.

14 Jul 2024

Lifestyle changes can greatly reduce heart disease risk in people with high genetic risk

Study highlights the significant impact of genetic risk and lifestyle on early- and late-onset cardiovascular diseases, showing that lifestyle improvements can notably reduce CVD risk, especially in high genetic risk individuals.

14 Jul 2024

New 3D model sheds light on amyloid-beta's impact

Researchers at the Terasaki Institute for Biomedical Innovation (TIBI) have unveiled a pioneering study shedding light on the intricate mechanisms underlying Alzheimer's disease (AD). The study, titled "Effects of amyloid-β-mimicking peptide hydrogel matrix on neuronal progenitor cell phenotype," represents a significant leap forward in understanding the interplay between amyloid-like structures and neuronal cells.

13 Jul 2024

Antibody-drug conjugate shows preclinical efficacy

A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, "Entering the golden age for antibody-drug conjugates in gynecologic cancer."

13 Jul 2024

Study links OCD improvement to brain activity shift

A recent study from Baylor College of Medicine and Texas Children's Hospital has identified a specific neural activity pattern as a novel biomarker to accurately predict and monitor the clinical status of individuals with obsessive-compulsive disorder (OCD) who have undergone deep brain stimulation (DBS), a rapidly emerging therapeutic approach for severe psychiatric disorders. The study, led by led by Drs. Sameer Sheth and Wayne Goodman along with co-lead authors, Drs. Nicole Provenza, Sandy Reddy, and Anthony Allam, was published in Nature Medicine.

13 Jul 2024

Gene editing silences mutant microRNA, restores hearing in adult mice

Researchers have used gene editing to restore hearing in adult mice with a type of inherited hearing loss. They showed that shutting down a damaged copy of a gene called a microRNA (miRNA) enabled the animals to regain hearing. The approach by a research team supported by the National Institutes of Health (NIH), reported in Science Translational Medicine, may eventually lead to potential treatments for inherited hearing loss in people.

13 Jul 2024

Revolutionary AI model improves early dementia diagnosis

Cambridge scientists have developed an artificially-intelligent tool capable of predicting in four cases out of five whether people with early signs of dementia will remain stable or develop Alzheimer’s disease.

13 Jul 2024

Innovative AI diabetes training module gets national recognition

The development of a new artificial intelligence-based tool that supports health professionals caring for people with diabetes has led to national recognition for a Northumbria University researcher and her team.

13 Jul 2024

Mainz Biomed seeks FDA’s Breakthrough Devices Designation for advanced colorectal cancer test

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced that it has submitted its application to the U.S. Food and Drug Administration (FDA) requesting Breakthrough Device Designation for its non-invasive Next Generation colorectal cancer (CRC) product including the Company’s novel portfolio of mRNA biomarkers. Subject to the FDA’s review, a Breakthrough Device Designation could significantly accelerate approval.

13 Jul 2024

Almirall's Ebglyss recommended by NICE for NHS atopic dermatitis patients

Almirall S.A., a global biopharmaceutical company dedicated to medical dermatology, announced today that the National Institute for Health and Care Excellence (NICE) has recommended Ebglyss (lebrikizumab) for use in moderate to severe Atopic Dermatitis in the NHS England.

13 Jul 2024

New threshold for CXCL13 concentration revolutionizes neuroborreliosis diagnosis

A newly defined threshold for the concentration of the cytokine CXCL13 may improve the diagnosis of neuroborreliosis.

13 Jul 2024

WISDOM project leverages AI and data to combat chronic immune-mediated diseases in Europe

Integrating medical and research data, ensuring secure data sharing, and using advanced AI models offer immense possibilities to mitigate the impact of chronic immune-mediated diseases (CIMDs) affecting 10% of Europeans.

12 Jul 2024

Short and long sleep duration linked to microvascular disease in newly diagnosed diabetics

New research to be presented at this year's Annual Meeting of the European Association for the Study of Diabetes (EASD) (Madrid, 9-13 September) shows that people recently diagnosed with diabetes who experience short or long sleep duration are more likely to experience microvascular disease (damage to the small blood vessels), which could ultimately lead to more serious complications.

12 Jul 2024

Study identifies RFC4 as key player in nasopharyngeal carcinoma

Lichuan Wu et al., at Medical College of Guangxi University, China, presented a comprehensive study on the role of replication factor C subunit 4 (RFC4) in nasopharyngeal carcinoma (NPC), a type of epithelial cancer commonly associated with Epstein-Barr virus infection.

12 Jul 2024

Understanding the connection between autistic traits and board gaming

Board gaming is a growing industry, and anecdotally popular among people who display autistic traits.

12 Jul 2024

Study reveals potential cognitive benefits of antidiabetic drugs

Investigators analyzing the potential cognitive effects of antidiabetic medications in records of more than 1.5 million patients with type 2 diabetes mellitus (T2DM) found risks of dementia and Alzheimer's disease (AD) were significantly lower in patients treated with metformin and sodium glucose co-transporter-2 inhibitors (SGLT-2i) compared to other antidiabetic drugs.

12 Jul 2024

Medical Condition News

AI analysis of Reddit reveals public interest in GLP-1 drugs for weight loss and mental health benefits

New brain targets for GLP1-based obesity drugs may reduce weight without nausea

Lifestyle changes can greatly reduce heart disease risk in people with high genetic risk

New 3D model sheds light on amyloid-beta's impact

Antibody-drug conjugate shows preclinical efficacy

Study links OCD improvement to brain activity shift

Gene editing silences mutant microRNA, restores hearing in adult mice

Revolutionary AI model improves early dementia diagnosis

Innovative AI diabetes training module gets national recognition

Mainz Biomed seeks FDA’s Breakthrough Devices Designation for advanced colorectal cancer test

Almirall's Ebglyss recommended by NICE for NHS atopic dermatitis patients

New threshold for CXCL13 concentration revolutionizes neuroborreliosis diagnosis

WISDOM project leverages AI and data to combat chronic immune-mediated diseases in Europe

Short and long sleep duration linked to microvascular disease in newly diagnosed diabetics

Study identifies RFC4 as key player in nasopharyngeal carcinoma

Understanding the connection between autistic traits and board gaming

Study reveals potential cognitive benefits of antidiabetic drugs

Discovering the cerebellum's new role in thirst modulation

Immune cell inflammation may be responsible for some severe symptoms in lysosomal storage diseases

Inulin gel-based oral immunotherapy is effective in suppressing food allergy responses and anaphylactic shock

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News